Mudan Granules for Diabetic Peripheral Neuropathy: A Systematic **Review of Preclinical and Clinical Evidence**

1	Jianlong Zhou ^{1¶} , Lv Zhu ^{2&} , Yadi Li ^{1*}
2	¹ Department of Traditional Chinese Medicine, People's Hospital of Deyang City, Deyang, China
3	² Department of Integrative Medicine, West China Hospital, Sichuan University, Chengdu, China
4	
5	
6	* Corresponding author:
7	E-mail: dido_lee0308@163.com (Yadi Li)
8	
9	
10	
11	
12	
13	
14	
15	
10	
10	
17	
18	
19	
20	
21	

22 Abstract

23 Background

24 Mudan granules has been used in China to treat diabetic peripheral neuropathy (DPN), but there is a

25 lack of systematic review of reports in this area. The aim of this systematic review was to evaluate

26 the efficacy and safety of Mudan granules in the treatment of diabetic peripheral neuropathy.

27 Methods

28 Initial studies were searched from PubMed, Embase, Cochrane, China National Knowledge

29 Infrastructure (CNKI), VIP database, Wanfang electronic databases. The Cochrane Risk of Bias tool

30 was used to evaluate the risk of bias. The meta-analysis was performed by Stata 16.0 software. For

31 dichotomous and continuous outcomes, the relative risk (RR) and standardized mean difference

32 (SMD) with 95% confidence interval (CI) were conducted, respectively.

33 **Results**

34 51 randomized controlled trials (RCTs) involving 5,416 patients were included. In the meta-analysis,

35 compared with routine treatment (RT) alone, Mudan granules plus RT reduced Toronto clinical

36 scoring system (TCSS) score (SMD, -0.52; 95% CI, -0.66 to -0.38; P < 0.01), total symptoms score

37 (TSS) (SMD, -1.44; 95% CI, -2.88 to -0.00; P = 0.05), serum homocysteine (Hcy) levels (SMD, -

38 3.84; 95% CI, -5.99 to -1.70; P < 0.01), serum high sensitive C-reactive protein (hs-CRP) levels

39 (SMD, -1.68; 95% CI, -3.29 to -0.08; P = 0.04), and improved total clinical efficacy (RR, 1.23; 95%

40 CI, 1.19 to 1.27; P < 0.01) and serum superoxide dismutase (SOD) levels (SMD, 1.54; 95% CI, 1.13

41 to 1.95; P < 0.01). Besides, Mudan granules presented an adjuvant efficacy on median motor nerve

42 conduction velocity (SMD, 1.61; 95% CI, 1.16 to 2.07), median sensory nerve conduction velocity

43 (SMD, 1.73; 95% CI, 1.26 to 2.20), common peroneal motor nerve conduction velocity (SMD, 1.48;

44 95% CI, 1.10 to 1.86), common peroneal sensory nerve conduction velocity (SMD, 1.57; 95% CI,

45	1.23 to 1.92), tibial motor nerve conduction velocity (SMD, 1.34; 95% CI, 0.82 to 1.87), and tibial
46	sensory nerve conduction velocity (SMD, 1.03; 95% CI, 0.86 to 1.20). In terms of adverse events,
47	there was no statistically significant difference between the trial group and the control group (P
48	=0.87). Five preclinical studies were also retrieved for the study. Animal studies have shown that
49	Mudan granules have anti-oxidative stress effects and could reduce the inflammatory response. It
50	may improve peripheral nerve injury in diabetic rats by modulating the TLR4/MyD88/NF- κ B
51	pathway, TLR4/p38 MAPK pathway and PI3K/AKT pathway.

52 **Conclusions**

53 Mudan granules presented an adjuvant efficacy on patients with DPN and could improve the 54 oxidative stress and inflammatory levels in preclinical models. However, high-quality original 55 studies are needed to further prove the evidence.

56 1. Introduction

57 Diabetic peripheral neuropathy is one of the most common chronic complications of diabetes, 58 occurring in approximately 50% of people with diabetes(1). It is also an important cause of lower 59 limb amputation and disabling neuropathic pain. It causes great suffering to patients in their daily 60 lives and places a heavy economic burden on the healthcare system and society as a whole(2). 61 Previous studies have reported prevalence rates of DPN ranging from 6% to 51%, with this variation 62 being related to the population studied(3). 50% of people with DPN are usually asymptomatic in the 63 early stages(4). There are also no simple markers for the early detection of DPN in routine clinical 64 practice. DPN is defined internationally as "diabetic patients accompanied by signs and/or symptoms 65 associated with peripheral nerve dysfunction after other causes have been excluded"(4). This 66 definition suggests that the diagnosis of DPN is comprehensive and exclusive. A diagnosis of DPN 67 requires 3 elements to be met. Firstly, it is necessary to have definite diabetes. Secondly, there must

68 be clinical evidence of the presence of peripheral neuropathy (signs or symptoms), and/or evidence of 69 electrophysiological examination. Finally, other causes of peripheral neuropathy need to be ruled out by relevant laboratory tests. The Toronto Consensus recommends the use of abnormal nerve 70 71 conduction studies (NCS) with signs or symptoms to diagnose DPN. The NCS is considered to be the 72 most important basis for the diagnosis of large fiber neuropathy. Screening for DPN involves a foot 73 examination and history taking for neurological symptoms, as well as screening tests such as the 128 74 Hz tuning fork vibration sensing test and the 10 g (Semmes-Weinstein) monofilament test(2). 75 However, these tests are unable to detect lesions in small nerve fibers. Skin biopsy is considered the 76 reference for identifying small fiber neuropathy. Nevertheless, mass screening and repeat biopsies are 77 not feasible(5). Therefore, the diagnosis of DPN, the determination of global prevalence and 78 incidence remains a challenging task.

79 Patients with DPN usually present with symmetrical pain in the extremities, especially in the distal 80 extremities. The most typical manifestation is abnormal sensation in the "glove-and-stocking" 81 distribution(6). Current clinical management focuses on glycemic control, foot care and pain 82 management(3). Strict glycemic control may stop the progression of diabetic neuropathy, but there is 83 no evidence that glycemic control relieves pain in DPN. For the management of pain in DPN, major 84 international clinical guidelines recommend several symptomatic treatment protocols(7). First-line 85 treatment options include tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors and 86 anticonvulsants that act on calcium channels. Pregabalin, gabapentin and duloxetine are the usual 87 first-line drugs. However, tricyclic antidepressants could cause dry mouth, orthostatic hypotension, 88 constipation, and urinary retention. Topical medications such as capsaicin and isosorbide nitrate may 89 be considered in the second- or third-line treatment. Opioids may not be recommended as a first- or 90 second-line treatment acute exacerbations since it is addictive(3, 8). Numerous treatments are 91 palliative in nature and do not target the underlying mechanism causing the pain. Specifically, alpha-

92 lipoic acid and epalrestat appear to modify disease state well by modulating pathogenesis but are not
93 recommend to by guidelines(8). Therefore, there is an urgent need to discover new therapeutic agents
94 that can target the mechanisms.

95 Traditional Chinese medicine (TCM) has a unique theoretical system. It has accumulated rich clinical 96 experience in the treatment of T2DM and related complications(9). The concept of DPN is not 97 clearly described in TCM. Based on the characteristics of "numbness, pain, coldness and limb 98 weakness", DPN belongs to the categories of "Xiaoke (emaciation and thirst)", "Xiaoke pulse Bi", 99 "Bi syndrome" and "Wei syndrome" in the concept of TCM(6, 10). Mudan granules is a Chinese 100 patent medicine consisting of Astragalus membranaceus (Huangqi), Corydalis rhizoma with vinegar 101 (Yanhusuo), Panax notoginseng (Sangi), Radix Paeoniae rubra (Chishao), Salvia miltiorrhiza 102 (Danshen), Ligusticum chuanxiong, safflower (Honghua), Logwood (Sumu), and Caulis Spatholobi 103 (Jixueteng)(11). It has the effects of invigorating Qi and promoting blood circulation, unblocking the 104 meridians, and relieving pain. In China it is approved for the treatment of DPN(6). A randomised 105 controlled trial including 148 patients with DPN showed that Mudan granules improved the 106 conduction velocity of the common peroneal and median nerves and were effective in relieving 107 clinical symptoms(12). Another study showed that Mudan granules combined with pancreatic 108 kininogenase increased serum SOD level, decreased serum hypersensitive C-reactive protein (hs-109 CRP) level and TCSS score, and improved sensory nerve function in DPN patients(13). Therefore, in 110 this systematic review, we evaluated clinical randomized controlled trials (RCTs) and pre-clinical 111 studies of Mudan granules combined with RT for DPN, in order to more objectively evaluate the 112 efficacy and safety of Mudan granules and to explore the potential mechanisms.

113 **2. Methods**

114 **2.1. Search strategy**

115	The meta-analysis followed the guidelines for Preferred Reporting Items for Systematic Reviews and
116	Meta-analyses (PRISMA)(14) (see S1 File for the PRISMA checklist). The study was registered on
117	the PROSPERO platform (CRD42022373113). The literature search was not restricted by language.
118	The literature search was conducted using combinations of the following words: "diabetic peripheral
119	neuropathy or diabetic or neuralgia" and "Mudan or Mu Dan". Electronic databases, including
120	PubMed, Embase, Cochrane, China National Knowledge Infrastructure (CNKI), VIP database,
121	Wanfang database were searched. The detailed search strategies were provided in the additional file
122	(see S2 File). In addition, we manually searched the reference lists of included clinical trials. The
123	retrieval time range was from the establishment of the database to October 2022. Two authors
124	(Jianlong Zhou and Lv Zhu) independently conducted the literature search based on the search
125	strategy. Disputed sections were resolved by the third author (Yadi Li).

126 **2.2. Eligible criteria**

127 The inclusion criteria were as follows: (I) the study participants were clinically diagnosed with DPN; 128 (II) the control group was treated as follows: routine treatment (e.g., diet modification, regular 129 exercise, blood glucose control, etc.) combined or not with western medicine for the treatment of 130 DPN; (III) Patients in the trial group were treated with Mudan granules on the basis of treatment in 131 the control group; (IV) the study design is RCTs or preclinical studies; (V) there is no restriction on 132 the duration of disease or treatment; (VI) outcome measures included at least one of effectiveness and 133 safety measure; effectiveness measures included total clinical efficacy (TCE), nerve conduction 134 velocity (NCV) including at least one of the median, common peroneal and tibial nerves, TCSS 135 score, TSS, serum homocysteine (Hcy) level, serum hs-CRP level, serum SOD level; safety measure 136 included adverse event rate.

The exclusion criteria were as follows: (I) duplicate literature; (II) review; (III) case report; (IV)
clinical experience; (V) data analysis; (VI) review; (VII) non-diabetic peripheral neuropathy; (VIII)
unrelated intervention; (IX) protocol or guideline; (X) non-randomised controlled trial; (XI) lack of
data.

141 **2.3. Study screening and Date extraction**

142 We used reference management software (EndNote 20) to screen the literature. First, duplicates were 143 identified and removed. Then, the literature was screened based on title and abstract. Finally, the full 144 text was reviewed for eligibility based on inclusion and exclusion criteria. Two researchers (JLZ and 145 LZ) independently assessed all retrieved literature and analysed the data according to 146 inclusion/exclusion criteria. Disagreements were resolved by the third researcher (YDL). The 147 relevant information was extracted and recorded using Microsoft excel software. The following 148 information was extracted: (1) basic information of the included studies, including year of 149 publication, name of first author, country or region, number of cases per group, baseline 150 characteristics of subjects (age); (2) intervention and course of treatment in the trial and control 151 groups; (3) outcome measures, including: total clinical efficacy (TCE), nerve conduction velocity 152 (NCV) including at least one of the median, common peroneal and tibial nerves, TCSS score, TSS, 153 serum homocysteine (Hcy) level, serum hs-CRP level, serum SOD level, adverse event. Data will be 154 cross-checked by the third researcher to ensure quality.

155 2.4. Quality assessment

156 The study quality was also evaluated independently by two researchers (ZJL and ZL) according to

- 157 the risk of bias assessment tool recommended by the Cochrane Systematic Review Manual (5.1.0).
- 158 The evaluation included the following 7 items: random sequence generation; allocation concealment;

blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data;
selective reporting; other sources of bias. Three levels of risk of bias were followed to assess: low
risk, unclear risk, and high risk. Risk of bias plots for the evaluation results were drawn using the R
package.

163 2.5. Data analysis

164 Stata 16.0 software (Stata Corporation, College Station, Texas, USA) was used for the meta-analysis

165 of all data. For dichotomous data, we calculated risk ratio (RR) and 95% confidence interval (CI).

166 Standardized mean difference (SMD) and 95% CI were calculated for continuous data. The statistical

167 significance of differences between groups was evaluated with the Z -test, and $P \le 0.05$ indicated

168 that the differences were statistically significant. The random-effect model of meta-analysis was used

169 in the study, assuming significant heterogeneity in all the included studies. Cochran's Q test and

170 Higgins' I^2 test were used to analyze the heterogeneity between studies. When P > 0.05 or $I^2 < 50\%$,

171 there is no significant heterogeneity between studies. Otherwise, it means there exists significant

172 heterogeneity among studies. In addition, Funnel plots were used to assess the publication bias.

173 L'Abbe plot were also used to test for heterogeneity.

174 **2.6.** Patient and public involvement

175 Patients and public were not involved in this study.

176 **3. Results**

177 **3.1. Literature search**

186	3.2. Characteristics
184 185	Fig 1. Flow chart of literature retrieval and inclusion.
183	flowchart of the retrieval is shown in Fig 1.
182	studies. Ultimately, 51 clinical studies were included in the meta-analysis(12, 13, 15-63). The
181	studies were included. All studies were conducted in China, with 51 clinical studies and 5 preclinical
180	initial screening of titles and abstracts. After reading the full text of the remaining 100 studies, 56
179	articles potentially relevant to this study were retained. Among these, 52 articles were excluded after
178	A total of 179 articles were retrieved according to the search strategy. After removing duplicates, 152

A total of 51 studies were included in this study for quantitative analysis, involving 5416 patients, including 2752 in the trial group and 2664 in the control group. The control group was treated as follows: RT (e.g., diet modification, regular exercise, blood glucose control, etc.) combined or not with RT for DPN. Patients in the trial group were treated with Mudan granules based on treatment in the control group. The basic information of the included literature is shown in **S1 Table**.

192 **3.3. Methodological quality**

The quality of the 51 included studies was assessed using the RCT risk of bias assessment tool recommended by the Cochrane Collaboration. The results of the risk of bias assessment are shown in **Figs 2** and **3**. Three studies grouped patients according to drug regimens(37, 45, 60) and two studies grouped patients according to order of admission(49, 50), all of whom were rated as high risk. 25 studies explicitly stated that patients were grouped according to rolling dice or random number table methods, all of which were rated as low risk. Studies that did not specify the method of randomization were rated as unclear risk. All randomized controlled trials without allocation

- 200 concealment and blinding were rated as unclear risk. All included studies showed a low risk of bias
- 201 in terms of selective reporting and incomplete outcome data. Three studies were rated as high risk in
- term of other sources of bias because the mean age of patients enrolled was not reported(22, 25, 55).
- 203 Fig 2. Risk of bias assessment of the included literature.
- 204 Fig 3. Bar chart of risk of bias assessment for the included literature.
- 205

206 3.4. Meta-analysis

207 **3.4.1.** Total clinical efficacy (TCE)

- A total of 41 articles reported TCE, and there was no significant heterogeneity between studies (I^2
- 209 = 20%, P = 0.26). The results of the meta-analysis indicated that the TCE of combining Mudan
- granules plus RT were 1.23 times (RR 1.23, 95% CI: 1.19 to 1.27, P < 0.01) more effective than the
- 211 RT for DPN, as shown in Fig 4. We also performed a heterogeneity test for TCE using the L'Abbe
- 212 plot. The L'Abbe plot showed that all studies were above the null line and that the studies showed a
- 213 more concentrated distribution. This also indicated that the efficacy of Mudan granules for DPN was
- superior to that of the control group, as shown in **Fig 5**.
- 215 Fig 4. Forest plot of total clinical efficacy.
- 216 Fig 5. L'Abbe plot of heterogeneity test for total clinical efficacy.

217 **3.4.2.** Median nerve conduction velocity

- 218 A total of 29 articles reported changes in median motor nerve conduction velocity before and after
- treatment. SMD (i.e., Cohen's d) was estimated using a random effect model. As shown in Table 1,
- the difference in median motor nerve conduction velocity before and after treatment with Mudan

221	granules based on the treatment of the control group for DPN was statistically significant (SMD 1.61,
222	95% CI: 1.16 to 2.07, $P < 0.01$). There was a high heterogeneity between studies ($I^2 = 96.07\%$, P
223	<0.01). A total of 27 articles reported changes in median sensory nerve conduction velocity before
224	and after treatment. As shown in Table 1, the difference in median sensory nerve conduction velocity
225	before and after treatment with Mudan granules was statistically significant compared with the
226	control group (SMD 1.73, 95% CI: 1.26 to 2.20, $P < 0.01$), and there was significant heterogeneity
227	between studies (I^2 =96.19%, $P < 0.01$). The above results suggested that Mudan granules were
228	effective in increasing median nerve conduction velocity of patients with DPN. The detailed results
229	were shown in S1 Fig.

Table 1. Meta-analysis results of other outcome measures. 230

Outcome measures	Pooled studies	Analysis mode	I ²	Effect size	Pooling value with 95% CI	Р
Median nerve MNCV	29	Random effect model	96.07%	SMD	1.61[1.16, 2.07]	<0.01
Median nerve SNCV	27	Random effect model	96.19%	SMD	1.73[1.26, 2.20]	< 0.01
Common peroneal nerve MNCV	38	Random effect model	96.34%	SMD	1.48[1.10, 1.86]	<0.01
Common peroneal nerve SNCV	35	Random effect model	95.15%	SMD	1.57[1.23, 1.92]	<0.01
Tibial never MNCV	8	Random effect model	92.73%	SMD	1.34[0.82, 1.87]	<0.01
Tibial never SNCV	5	Random effect model	0%	SMD	1.03[0.86, 1.20]	< 0.01
TCSS score	9	Random effect model	0%	SMD	-0.52[-0.66, -0.38]	<0.01
TSS	5	Random effect model	97.44%	SMD	-1.44[-2.88, -0.00]	0.05

Serum Hcy level	5	Random effect model	98.42%	SMD	-3.84[-5.99, -1.70]	<0.01
Serum hs-CRP level	11	Random effect model	99.39%	SMD	-1.68[-3.29, -0.08]	0.04
Serum SOD level	15	Random effect model	92.44%	SMD	1.54[1.13, 1.95]	<0.01
Adverse event	20	Random effect model	0%	RR	0.96[0.63, 1.48]	0.87

Note. MNCV, Motor nerve conduction velocity; SNCV, Sensory nerve conduction velocity; TCSS, Toronto clinical scoring system; TSS, Total symptom score; hs-CRP, Hypersensitive C-reactive protein; SOD, Superoxide dismutase; Hcy, Homocysteine.

231

232 **3.4.3.** Common peroneal nerve conduction velocity

233 A total of 38 articles reported changes in common peroneal motor nerve conduction velocity before 234 and after treatment. As shown in **Table 1**, the difference in common peroneal motor nerve 235 conduction velocity before and after treatment with Mudan granules based on the treatment of the 236 control group for DPN was statistically significant (SMD 1.48, 95% CI: 1.10 to 1.86, P < 0.01). There was significant heterogeneity between studies ($I^2 = 96.34\%$, P < 0.01). A total of 35 articles 237 238 reported changes in common peroneal sensory nerve conduction velocity before and after treatment. 239 Compared with the control group, there was a statistically significant difference in the conduction 240 velocity of the common peroneal sensory nerve before and after treatment with Mudan granules 241 (SMD 1.57, 95% CI: 1.23 to 1.92, P < 0.01), and there was significant heterogeneity between studies 242 $(I^2 = 95.15\%, P < 0.01)$. The above results suggested that Mudan granules were effective in increasing 243 the common peroneal nerve conduction velocity in DPN patients. The detailed results were shown in 244 S2 Fig.

245 **3.4.4.** Tibial nerve conduction velocity

246 A total of 8 studies reported changes in tibial nerve motor nerve conduction velocity before and after 247 treatment. As shown in Table 1, the difference in tibial nerve motor nerve conduction velocity before 248 and after treatment with Mudan granules was statistically significant based on the treatment of DPN 249 in the control group (SMD 1.34, 95% CI: 0.82 to 1.87, P < 0.01). There was significant heterogeneity 250 between studies ($I^2 = 92.73\%$, P < 0.01). A total of 5 articles reported changes in tibial nerve sensory 251 nerve conduction velocity before and after treatment. The difference in tibial nerve sensory nerve 252 conduction velocity before and after treatment with Mudan granules was statistically significant 253 compared with the control group (SMD 1.03, 95% CI: 0.86 to 1.20, P < 0.01), and there was no 254 heterogeneity between studies ($I^2 = 0\%$, P = 0.39). These results suggested that Mudan granules could 255 effectively improve tibial nerve conduction velocity in DPN patients. The detailed results were 256 shown in S3 Fig.

257 **3.4.5.** Toronto Clinical Scoring System (TCSS) score

A total of 9 studies reported changes in the TCSS score before and after treatment. The results of the meta-analysis showed that there was a statistically significant difference in TCSS score before and after treatment with Mudan granules compared with the control group (SMD -0.52, 95% CI: -0.66 to -0.38, P < 0.01). There was a low heterogeneity between studies ($I^2 = 0\%$, P = 0.76), as shown in **Table 1** and **S4 Fig**. This suggested that Mudan granules may effectively reduce the TCSS score of DPN patients.

264 **3.4.6.** Total Symptom Score (TSS)

A total of 5 articles reported changes in TSS before and after treatment. There was a high heterogeneity between studies ($I^2 = 97.44\%$, P < 0.01). The difference in TSS before and after

- 267 treatment with Mudan granules was statistically significant compared to the control group (SMD -
- 268 1.44, 95% CI: -2.88 to -0.00, P = 0.05). This indicated that Mudan granules could effectively reduce
- 269 TSS in DPN patients. As shown in **Table 1** and **S5 Fig**.

270 **3.4.7.** Serum Hcy level

- 271 A total of 5 articles reported changes in serum Hcy level before and after treatment. Compared with
- 272 RT, serum Hcy level was significantly lower in Mudan granules plus RT treatment (SMD -3.84, 95%
- 273 CI: -5.99 to -1.70, P < 0.01), and there was significant heterogeneity between studies ($I^2 = 98.42\%$, P
- 274 <0.01). As shown in **Table 1** and **S6 Fig**.

275 **3.4.8.** Serum hs-CRP level

- A total of 11 studies reported the changes in serum hs-CRP level before and after treatment.
- 277 Compared with RT, serum hs-CRP level was significantly lower in Mudan granules plus RT
- treatment (SMD -1.68, 95% CI: -3.29 to -0.08, P = 0.04), and there was significant heterogeneity
- between studies ($l^2 = 99.39\%$, P < 0.01). As shown in **Table 1** and **S7 Fig**.

280 **3.4.9.** Serum SOD level

A total of 15 studies reported changes in serum SOD level before and after treatment. Compared with

- 282 RT alone, serum SOD level was significantly higher in Mudan granules plus RT treatment (SMD
- 1.54, 95% CI: 1.13 to 1.95, P < 0.01), and there was a high heterogeneity between studies (I^2
- 284 =92.44%, *P* <0.01). As shown in **Table 1** and **S8 Fig**.

285 **3.4.10.** Adverse event

- A total of 20 studies reported the adverse events, with a low heterogeneity between studies ($I^2 = 0\%$,
- P = 0.89). The difference in the rate of adverse event after Mudan granules treatment was not

statistically significant compared with the control group (RR 0.96, 95% CI: 0.63 to 1.48, P = 0.87), as shown in **Table 1** and **S9 Fig**. Both had low rates of adverse events, and no serious adverse events were reported.

291 3.4.11. Sensitivity analysis

For outcome measures without significant statistical heterogeneity, the results of the random effect model were compared with those of the fixed effect model, and the results showed that the analysis was stable and reliable.

295 **3.4.12.** Publication bias analysis

We performed a funnel plot analysis of total clinical efficacy. The funnel plot showed an uneven distribution of studies, which implies a possible publication bias, as shown in **Fig 6**. The following problems existed in the literature analysis: the large number of studies with low sample size, poor methodological design of the studies, etc. All the above factors may have caused the funnel plot to show an uneven distribution.

Fig 6. Funnel plot of the total clinical efficacy of the two groups of patients.

302

303 **3.4.13.** Analysis of the results of preclinical studies

304 We included 5 preclinical studies. After analyzing these articles, we summarized the possible

305 mechanisms of Mudan granules for DPN, as shown in Fig 7. Animal experiments have shown that

- 306 Mudan granules could improve sciatic nerve conduction velocity(64) and reduce inflammatory
- 307 response by decreasing serum Hcy and TGF-β1 levels(65). Mudan granules are also able to increase
- 308 serum glutathione (GSH) and SOD levels and reduce serum malondialdehyde (MDA) levels(66),
- 309 which indicated its ability to resist oxidative stress. Several studies have also found that Mudan

310 granules could improve peripheral nerve injury by modulating the TLR4/MyD88/NF- κ B pathway

311 and the TLR4/p38 MAPK pathway(67). It may also alleviate neuropathic pain in diabetic rats by

312 modulating the PI3K/AKT signaling pathway(68).

313 Fig 7. Mechanistic plot of Mudan granules in the treatment of DPN.

314 **4. Discussion**

315 In the study, we evaluated the efficacy and safety of Mudan granules in patients with DPN and 316 explored the relevant mechanisms. Previous study included 11 RCTs and found that Mudan granules 317 had a significant advantage over RT alone for DPN in terms of overall efficiency and improvement in 318 the conduction velocity of the common peroneal, median, and tibial nerves. Its conclusion was that 319 Mudan granules was effective and safe in the treatment of DPN(69). Our study also showed that 320 Mudan granules was effective and safe in the treatment of DPN, with results consistent with previous 321 meta-analysis. However, the main problems with these early studies were the limited sample size and 322 the small number of outcome measures. Our study included studies from 2017 onwards and added 323 outcome indicators such as TCSS score, TSS, Hcy, hs-CRP, and SOD. This study showed that 324 compared with the control group, Mudan granules was able to reduce TCSS score and TSS, lower 325 serum Hcy and hs-CRP levels, and increase SOD level.

Except for the low heterogeneity of outcome measures such as total clinical efficacy, TCSS score, tibial sensory nerve conduction velocity, and adverse event, the heterogeneity of Meta-analysis was greater for other measures, which may be related to the following two reasons. First, the Western medicine treatment measures were inconsistent between studies. For example, in some studies, the control group was treated with mecobalamin in addition to routine treatment, while in others it was combined with lipoic acid, and in still others, the control group was treated with epalrestat or other

drugs. Second, the duration of therapy varied between studies. Some studies had a treatment duration
of 2 weeks, while some studies had a treatment duration of 4 weeks, and others had a treatment
duration of 12 weeks.

335 There are several limitations to this meta-analysis that need to be addressed. First, despite the 336 inclusion of RCTs, the main studies included had large biases in the methodological design, for 337 example, all studies did not specify allocation concealment and blinding. Only 25 studies provided 338 sufficient information about the randomization process. Second, for most of the studies, the treatment 339 duration was not long enough to properly assess the efficacy of Mudan granule treatment. This is 340 because DPN is a chronic disease that requires long-term treatment. The long-term efficacy and 341 safety studies are essential to determine the therapeutic utility of the drug. However, the duration of 342 treatment in the included studies ranged from 1 to 12 weeks, and long-term follow-up studies may 343 yield different results. Therefore, we were unable to assess the long-term safety and efficacy of 344 Mudan granules for the treatment of DPN. Third, study sample sizes were generally small, and most 345 studies did not involve formal prior sample size calculations. Hence, the use of large samples in 346 RCTs is needed to further validate the findings and avoid overestimation of intervention benefits due 347 to insufficient sample size. Finally, although we retrieved studies published in English or Chinese 348 databases, the language of the final included studies was Chinese, and studies published from other 349 languages were missing. Our findings may not be well disseminated.

The pathogenesis of DPN is still not fully elucidated. It is commonly believed that DPN is associated with hyperglycemia, hyperlipidemia, insulin resistance and protein metabolism(5). Some studies have found that serum Hcy level was closely related to the development of DPN(70). High Hcy levels can influence the function of insulin sensitivity, oxidative stress, nitric oxide, and the pathways of vascular and neurological damage(71). Studies have shown that serum CRP levels were found to be an independent predictor of the presence of DPN(72). Elevated serum TNF-α and IL-10 and CRP

17

356 is a phenomenon associated with a pro-inflammatory response to diabetes, which was also associated 357 with diabetic neuropathy(73). Oxidative stress caused by hyperglycemia was considered to be the 358 initiating factor in the pathogenesis of DPN(74). Some other studies have shown that SOD is an 359 important antioxidant enzyme. In DPN rats, serum SOD was decreased, while serum MDA was 360 significantly increased (74). Our study found that Mudan granules were able to reduce serum Hcy, hs-361 CRP and MDA levels and increase serum SOD levels, which showed its anti-inflammatory and anti-362 oxidative stress abilities. Some studies have found that insulin deficiency or insulin resistance caused 363 insulin receptors to promote apoptosis via the P13K/AKT pathway(6). Defective endoneurial 364 microvasculature may lead to hypoxia and ischemia, generation of oxidative stress, and activation of 365 the redox-sensitive transcription factor NF κ B(5). Our study found that Mudan granules may improve 366 peripheral nerve injury by modulating the TLR4/MyD88/NF-κB pathway and TLR4/p38 MAPK 367 pathway and alleviate neuropathic pain in diabetic rats by modulating the PI3K/AKT signaling 368 pathway. Other studies have found that the potential mechanisms of Mudan granules for DPN may 369 include improving insulin resistance, reducing islet cell apoptosis, neuroprotection, and other 370 effects(11, 75). Increasing evidence has suggested(76-78) that hyperlipidemia contributes to the 371 progression of diabetic neuropathy. Total cholesterol, triglycerides, and low-density lipoprotein 372 (LDL) cholesterol have been proved to be associated with DPN. A study on Mudan granules for 373 diabetic dorsalis pedis atherosclerosis showed that Mudan granules could reduce serum total 374 cholesterol, triglycerides, and LDL cholesterol levels(79). This predicted that Mudan granules may 375 treat DPN by regulating lipid metabolism, and further studies on the lipid metabolism-related 376 pathways of Mudan granules for DPN could follow. These studies above showed that Mudan 377 granules may improve the development of DNP through a multi-target and multi-pathway approach.

378 **5.** Conclusions

18

- 379 Our systematic and meta-analytic study provides supportive evidence that Mudan granules are
- 380 effective in the treatment of DPN patients based on RT, and no serious adverse events were observed.
- 381 High-quality studies are essential to be conducted and further prove the preliminary evidence from
- 382 the preclinical studies and clinical studies. Additionally, prolonged observation and follow-up are
- also needed to demonstrate the long-term efficacy and safety of Mudan granules.

384 Acknowledgments

385 None.

386 Authors' Contributions

- Jianlong Zhou: Conceived and designed the study, drawn up the manuscript and analysed the data,
- 388 prepared figures and/or tables. Lv Zhu: collected the data and performed the analysis. Yadi Li:
- 389 supervised and revised the manuscript. All authors read and approved the manuscript.
- 390

391 **Reference**

Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in Screening, Early
 Diagnosis and Accurate Staging of Diabetic Neuropathy. Front Endocrinol. 2021;12:25.

 Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR, Walker J, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019;7(12):938-48.

- 397 3. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease
 398 in Diabetes. Curr Diabetes Rep. 2019;19(10):8.
- 399 4. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic
 400 Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care.
 401 2017;40(1):136-54.
- 402 5. Burgess J, Frank B, Marshall A, Khalil RS, Ponirakis G, Petropoulos IN, et al. Early
 403 Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres. Diagnostics.
 404 2021;11(2):39.
- 405 6. Yang K, Wang Y, Li YW, Chen YG, Xing N, Lin HB, et al. Progress in the treatment of
 406 diabetic peripheral neuropathy. Biomed Pharmacother. 2022;148:10.

407 Khdour MR. Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol. 7. 408 2020;72(7):863-72. 409 8. Rafiullah M, Siddigui K. Pharmacological Treatment of Diabetic Peripheral Neuropathy: An 410 Update. CNS Neurol Disord-Drug Targets. 2022;21(10):884-900. 411 9. Zheng WJ, Wang GF, Zhang Z, Wang ZG, Ma K. Research progress on classical traditional 412 Chinese medicine formula Liuwei Dihuang pills in the treatment of type 2 diabetes. Biomed 413 Pharmacother. 2020;121:7. 414 10. Piao YL, Liang XC. Chinese Medicine in Diabetic Peripheral Neuropathy: Experimental 415 Research on Nerve Repair and Regeneration. Evid-based Complement Altern Med. 2012;2012:13. 416 Zhang YH, Jin D, Duan YY, Hao R, Chen KY, Yu TY, et al. Efficacy of Mudan Granule 11. 417 (Combined With Methylcobalamin) on Type 2 Diabetic Peripheral Neuropathy: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm, Multi-Center Trial. Front Pharmacol. 418 419 2021;12:10. 420 12. Xie X. Randomized parallel controlled study of treating type 2 diabetic peripheral neuropathy by Mudan particles plus western medicine. J Pract Tradit Chin Intern Med. 2012;26(05):53-4 (in 421 422 Chinese). 423 13. Sun J. Mudan granule and kallidinogenase in treatment of DPN patients and the influence on 424 SOD and hs-CRP. Liaoning J Tradit Chin Med. 2022;49(03):127-30 (in Chinese). 425 14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The 426 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 427 428 15. Zheng M, Du YB, Chen BQ, Wei GZ, Zhao Y. Clinical study of antioxidant stress of 429 integrated traditional Chinese and western medicine on diabetic peripheral neuropathy. Yunnan J 430 Tradit Chin Med Materia Med. 2016;37(02):30-1 (in Chinese). 431 16. Shen YD, Wu JF. Clinical study on kallidinogenase, Mudan granule and meeobalamin in 432 treatment of diabetic neuropathy. Diabetes New World. 2018:21(22):14-7 (in Chinese). 433 17. Wang YN, Yu SJ. Clinical observation of Mudan graule on the treatment of diabetic peripheral neuropathy. J Liaoning Univ Tradit Chin Med. 2016;18(6):87-9 (in Chinese). 434 435 18 Xia XH, Yan LH, Wang HD. Effectiveness of Mudan granules in the treatment of patients 436 with diabetic peripheral neuropathy. Henan Med Res. 2020;29(24):4557-9 (in Chinese). 437 Zhang JJ, Cao W, Zhao YJ, Hu B, Wu YP. The curative effect of Mudan granule in the 19. 438 treatment of diabetic peripheral neu-ropathy and its influence on serum oxidative stress, inflammatory 439 factors and pain substance levels. World J Integr Tradit West Med. 2021;16(12):2265-70 (in 440 Chinese). 441 20. Mi YX, Mi YX, Zhou FJ. Clinical research on Mudan Granule in treating diabetic peripheral 442 neuropathy. Journal of Hunan Univ of CM. 2013;33(11):65-7. Li J. Fan FW. Tu Y. Clinical efficacy and safety of mudan granules in the treatment of 443 21 444 diabetic peripheral neuropathy. Chin J Clin Rati Drug Use. 2019;12(09):70-1 (in Chinese). 445 22. Bai HC. Clinical observation of Mu Dan particles to treat diabetic peripheral neuropathy. 446 World Notes on Antibiotics. 2013;34(03):133-4 (in Chinese).

447 23. Dong M, Wen ZJ, Song YQ, Chen J. The efficacy of Mudan granules in the treatment of 448 diabetic peripheral neuropathy. Liaoning J Tradit Chin Med. 2015;42(07):1278-9 (in Chinese). 449 24. Zhang J, Qiu SL, Liang YH, Jin M. Clinical efficacy of Mudan granules in the treatment of 450 diabetic peripheral neuropathy with Qi deficiency and blood stasis. Beijing J Tradit Chin Med. 451 2016;35(12):1166-8 (in Chinese). 452 25 Tian H. Y., Zhang ZG, Comparison of the efficacy of mudan granules and micropowder in 453 the treatment of diabetic peripheral neuropathy. Mod J Integr Tradit Chin West Med. 454 2011;20(25):3166-7 (in Chinese). 455 26. Lin JH. Clinical observation of Mu Dan granule combined with mecobalamin in the treatment 456 of diabetic peripheral neuropathy. Chinese Community Doctors. 2014;30(20):101-2 (in Chinese). 457 Tian W. Efficacy of the Mudan granule plus conventional western medicine on diabetic 27. 458 peripheral neuropathy and its electromyography. Clin J Chin Med. 2019;11(05):74-6 (in Chinese). 459 28. Zhao D. Impact of Mudan granule plus insulin on nerve conduction velocity of diabetic 460 peripheral neuropathy patients. Liaoning J Tradit Chin Med. 2022;49(01):116-9 (in Chinese). 461 29. Wang LN, Du J, Wen ZJ, Yan Y. Efficacy of mudan granules combined with epalrestat in the 462 treatment of diabetic peripheral neuropathy. Liaoning J Tradit Chin Med. 2016;43(09):1890-1 (in 463 Chinese). 464 30. Liu L, Qin GJ. Efficacy of mudan granules combined with epalrestat in the treatment of diabetic peripheral neuropathy in the elderly and the effect on homocysteine. Chin J Pract Med. 465 466 2015;42(01):85-6 (in Chinese). 467 31 Lai J, Wang LF, Zeng JR. A comparative study on the clinical efficacy of Mudan granules combined with western medicine in the treatment of diabetic peripheral neuropathy. Asia-Pacific 468 469 Traditional Medicine. 2014;10(03):99-100 (in Chinese). 470 32. Chen D. Effect of Mudan granules combined with calcium hydroxybenzene sulfonate in the 471 treatment of patients with diabetic peripheral neuropathy. Medical Journal of Chinese People's 472 Health. 2021;33(10):85-7 (in Chinese). 473 33. Cui M, Peng YP, Gao JQ, Li S, Yang XS. Effects of Mudan granule combined with calcium 474 dobesilate capsules on nerve conduction velocity, hemorheology and oxidative stress in patients with 475 diabetic peripheral neuropathy. Pro Mod Biomed. 2021;21(22):4270-4 (in Chinese). 476 34. Zu O, Xu BX. Effect of Mudan granules combined with alprostadil on nerve conduction 477 velocity in patients with diabetic peripheral neuropathy. Chin J Rati Drug Use. 2019;16(10):12-4 (in 478 Chinese). 479 Zhang YP, Peng XF, He F, Mao YL, Cai SY. Effect of Mudan particles combined with 35. 480 methylcobalamin and lipoic acid for diabetic peripheral neuropa-thy. Journal of North China University of Science and Technology Health Sciences Edition. 2016;18(06):454-7 (in Chinese). 481 482 Deng XJ, Ren HS. Effect of Mudan granule and thiocyanic acid injection on inflammation 36 483 response and hemodynamic index in patients with diabetic peripheral neuropathy. The Medical 484 Forum. 2020;24(16):2234-7 (in Chinese). 485 Yu L, Zhang W, Fu WT, Effects of Mudan granule combined with lippic acid injection on 37. 486 TSS score and serum levels of SOD and Hcy in diabetic peripheral neuropathy patients. Sichuan J 487 Physiol Sci. 2022;44(01):30-3 (in Chinese).

488 38. Gao HP. Mudan granules combined with lipoic acid and methylcobalamin for diabetic 489 peripheral neuropathy. Pract Clin J Integr Tradit Chin West Med. 2018;18(02):19-21 (in Chinese). 490 39. Oi Y, Yu SJ. The clinical effect of Mudan particles combined with mecobalamine in the 491 treatment of painful diabetic peripheral neuropathy. World Chinese Medicine. 2015;10(03):356-8 (in 492 Chinese). 493 40 Oi JZ, Li L, Wang XM, Bai XP, Clinical efficacy of mudan granules combined with 494 methylcobalamin in the treatment of diabetic peripheral neuropathy. J Med Theor & Prac. 495 2019;32(11):1678-9 (in Chinese). 496 41. Wu WY. Effect of Mudan granule combined with mecobalamin for the treatment of diabetic 497 peripheral neuropathy and the impact on nerve conduction velocity. Clin Med Eng. 498 2018;25(08):1071-2 (in Chinese). 499 42 Chang C, Li Y. Clinical study of Mudan granule combined with Mecobalamin in treatment of 500 diabetic peripheral neuropathy. Chin J Gen Pract. 2017;15(05):792-5 (in Chinese). Xu T, Hao LM, Zhang Y, Liu CC, Liu HX. The effect of Mudan granule combined with 501 43. 502 macobalamine in the treatment of diabetic peripheral neuropathy. World Chinese Medicine. 503 2017;12(02):266-8 (in Chinese). 504 44. Zou H, Zhang G. Clinical observation on the treatment of type 2 diabetic peripheral 505 neuropathy with Mudan granules combined with methylcobalamin. J Xinxiang Med Coll. 2013:30(09):759-60. 506 507 45. Qu Y, Zhang YP. Study of Mudan grabule combined with mecobalamin and a-lipoic acid in 508 the treatment of diabetic peripheral neuropathy. Clin Res Pract. 2016;1(20):22-3 (in Chinese). 509 46. Xie YQ. Effect of Mudan granules, mecobalamine and α -lipoic acid in oxidative stress for 510 diabetic peripheral neuropathy patients. Liaoning J Tradit Chin Med. 2019;46(10):2109-11 (in 511 Chinese). 512 47. Wu XF, Luo XH, Xu J, Xu RY, Hou HB. Effect of MuDan particles combined with cobalt 513 amine and α -lipoic acid on diabetic peripheral neuropathy. Chin J Gen Pract. 2015;13(12):1966-514 7+2029(in Chinese). 515 48. Yang LM, Jia RM, Gao O, Yi JD, Li YZ. Therapeutic effect of Mudan granule combined 516 with Mecobalamin on DPN (syndrome of deficiency of Qi)and collaterals and its influence on 517 neuroelectrophysiology and oxidative stress index. J Clin Exp Med. 2020;19(02):181-4 (in Chinese). 518 49 Zhou MQ. Efficacy of Mudan particles with methylcobalamin and gabapentin on patients 519 with painful diabetic peripheral neuropathy. Liaoning J Tradit Chin Med. 2016;43(11):2317-9 (in 520 Chinese). 521 Wang X, Cui HM, Ren F, Kong C, He Y. Effectiveness of mudan granules combined with 50. 522 methylcobalamin and alpha-lipoic acid in the treatment of diabetic peripheral neuropathy. Clin Med 523 Chin. 2015;31(02):124-6 (in Chinese). 524 51. Chen Y. Effects of Mudan granule combined with insulin glargine on painful diabetic 525 peripheral neuropathy. Chin J Pract Med. 2020;47(15):108-11 (in Chinese). 526 Wu Y. Effect of Mudan granule combined with routine western medicine on nerve 52. 527 conduction velocity and its curative effect on diabetic peripheral neuropathy. Liaoning J Tradit Chin 528 Med. 2021;48(01):112-5 (in Chinese).

- 529 53. Wu HJ, Shi F, Zhang Y, Song XJ, Wang YL. Study on the effect of Mudan granule combined 530 with beraprost sodium and epalrestat in the treatment of diabetic peripheral neuropathy. Diabetes 531 New World. 2021;24(05):177-8+85 (in Chinese).
- 532 54. Wang LN, Du J, Dong M, Wen ZJ. Effect of Mudan granules, beraprost sodium tablets and 533 epalrestat on diabetic peripheral neuropathy. Liaoning J Tradit Chin Med. 2019;46(11):2354-7 (in 534 Chinese).
- 535 55. Feng CE, Shi ZD. Efficacy of Mudan particles combined beraprost and epalrestat for diabetic 536 peripheral neuropathy. Evaluation and Analysis of Drug-Use in Hospitals of China. 2015;15(01):44-6 537 (in Chinese).
- 538 56. Rao XJ, Wu YM. Clinical therapeutic observation of Mudan granule plusα-lipoic acid in
 539 patients with diabetic peripheral neuropa-thy. Chin J Pract Nerv Dis. 2019;22(04):370-3 (in Chinese).
- 540 57. Mei LN, Wu CA. 46 cases of diabetic peripheral neuropathy treated with mudan granules 541 combined with alpha-lipoic acid. Zhejiang J Tradit Chin Med. 2017;52(01):70 (in Chinese).
- 542 58. Qi Y, Yu SJ. Effect of mudan granules on oxidative stress in painful diabetic peripheral
 543 neuropathy. Lishizhen Med Mater Med Res. 2015;26(7):1561-3 (in Chinese).
- 544 59. Lu L, Wu L. Evaluation of the efficacy of Mudan granules in diabetic peripheral neuropathy.
 545 Chin Remed Clin. 2021;21(13):2294-5 (in Chinese).
- 54660.Zhu ZQ, Cheng SJ. Effectiveness of methylcobalamin combined with Mudan granules in the547treatment of diabetic peripheral neuropathy. Mod Pract Med. 2017;29(04):503-4 (in Chinese).
- 548 61. Wang Y, Liu L. Effectiveness of methylcobalamin combined with mudan granules in the
 549 treatment of diabetic peripheral neuropathy. Women's Health Research. 2019(19):123-4 (in Chinese).
- 550 62. Wen BH, Shen SM. Comparison of the curative effect of different regimens on diabetic
 551 peripheral neuropathy. J Hunan Norm Univ (Med Sci). 2018;15(03):81-4 (in Chinese).
- 552 63. Xia CJ. Effect of combined treatment of diabetic peripheral neuropathy with α -lipoic acid and 553 Mudan granules on Hcy and clinical effects. Chin Foreign Med Res. 2016;14(09):61-3 (in Chinese).
- 554 64. Yang WQ, Yu YB, Xu XL, Ren HX, Liang JF, Zhang L. Efficacy of Mu Dan granules on
 555 experimental rats with diabetic peripheral neuropathy. Chin J Diabetes. 2015;23(12):1099-102 (in
 556 Chinese).
- 557 65. Sun YM, Zhao HH, Yin YL, Wang L. Effect of Mudan granule on Hcy and TGF-β1 in serum
 558 of rat with diabetic peripheral neuropathy in different course of disease. Shanxi J of TCM.
 559 2021;37(10):51-3 (in Chinese).
- 560 66. Li YY, Yu SJ. The Effect of Mudan Particles on the Oxidative Levels of Spinal Cord of
 561 Diabetic Rats. Medical Recapitulate. 2016;22(10):2070-3 (in Chinese).
- 562 67. Zhou M, Yao WJ. Study on Regulatory Effects of Mudan Granules on TLR4-related Pathway
 563 in DPN Rats. Western J of TCM. 2021;34(10):52-6 (in Chinese).
- 68. Qi Y, Liu YT, Zhang H, Zhao ZJ. Research of Mudan granule improved neuropathic pain in
 diabetic rats by regulating PI3K/AKT pathway. Chin J Diffic and Compl Cas. 2021;20(02):176-81
 (in Chinese).
- 567 69. Fang ZH, Chen XQ, Chen YM, Qiu JJ, Yang C. Meta-analysis of the efficacy of Mudan
- 568 granules in the treatment of diabetic peripheral neuropathy. Journal of New Chinese Medicine.
- 569 2017;49(08):154-8 (in Chinese).

570 70. Lin XY, Sun T, Yu RX, Tang YL, Li HY. Correlation between elevated serum homocysteine 571 level and the development of diabetic peripheral neuropathy: a comparative study and meta-analysis.

572 Int J Clin Exp Med. 2016;9(2):2857-64.

573 71. Zhao JD, Li Y, Xin L, Sun M, Yu CJ, Shi GB, et al. Clinical Features and Rules of Chinese
574 Herbal Medicine in Diabetic Peripheral Neuropathy Patients. Evid-based Complement Altern Med.
575 2020;2020:8.

576 72. Canpolat AG, Emral R, Keskin C, Canlar S, Sahin M, Corapcioglu D. Association of
577 monocyte-to-high density lipoprotein-cholesterol ratio with peripheral neuropathy in patients with
578 Type II diabetes mellitus. Biomark Med. 2019;13(11):907-15.

- 579 73. Nadi M, Bambaeichi E, Marandi SM. Comparison of the effect of two therapeutic exercises
 580 on the inflammatory and physiological conditions and complications of diabetic neuropathy in female
 581 patients. Diabetes Metab Syndr Obes. 2019;12:1493-501.
- 582 74. Zhang YZ, Zhou ZC, Song CY, Chen X. The Protective Effect and Mechanism of
 583 Dexmedetomidine on Diabetic Peripheral Neuropathy in Rats. Front Pharmacol. 2020;11:11.

584 75. Liu S-N, Sun S-J, Liu Q, Hou S-C, Shen Z-F. Effect of Mudan Granule on islets beta cell 585 function in monosodium glutamate induced obese mice with insulin resistance: an experimental 586 study. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi Jiehe Zazhi= Chinese Journal of 587 Integrated Traditional and Western Medicine. 2014;34(7):853-8.

- 588 76. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AAF, Feldman EL. Elevated
 589 Triglycerides Correlate With Progression of Diabetic Neuropathy. Diabetes. 2009;58(7):1634-40.
- 590 77. O'Brien PD, Guo K, Eid SA, Rumora AE, Hinder LM, Hayes JM, et al. Integrated lipidomic
 591 and transcriptomic analyses identify altered nerve triglycerides in mouse models of prediabetes and
 592 type 2 diabetes. Dis Model Mech. 2020;13(2):12.

593 78. Naqvi S, Imani S, Hosseinifard H, Wen QL, Shahzad MN, Ijaz I, et al. Associations of serum
594 low-density lipoprotein and systolic blood pressure levels with type 2 diabetic patients with and
595 without peripheral neuropathy: systemic review, meta-analysis and meta-regression analysis of
596 observational studies. BMC Endocr Disord. 2019;19(1):16.

597 79. Guo Y, Sun Q. Effect of Mudan granule combined with zinc sulfate on ankle brachial index
598 in diabetic foot dorsal artery sclerosis and its efficacy. Chinese Journal of Biochemical
500 Pharma conting, 2016;151.4

- 599 Pharmaceutics. 2016:151-4.
- 600

601 Supporting information

- 602 S1 File. PRISMA checklist.
- 603 S2 File. The search strategies of English databases.
- 604 S1 Table. The basic information of the included literature.

- 605 S1 Fig. (A) Forest plot of the improvement of median motor nerve conduction velocity by
- 606 Mudan granules. (B) Forest plot of the improvement of median sensory nerve conduction
- 607 velocity by Mudan granules.
- 608 S2 Fig. (A) Forest plot of Mudan granules improving the common peroneal motor nerve
- 609 conduction velocity. (B) Forest plot of Mudan granules improving the common peroneal
- 610 sensory nerve conduction velocity.
- 611 S3 Fig. (A) Forest plot of Mudan granules improving the tibial motor nerve conduction
- 612 velocity. (B) Forest plot of Mudan granules improving the tibial sensory nerve conduction
- 613 velocity.
- 614 S4 Fig. Forest plot of Mudan granules for reducing TCSS score.
- 615 S5 Fig. Forest plot of TSS reduction by Mudan granules.
- 616 S6 Fig. Forest plot of Mudan granules reducing serum Hcy level.
- 617 S7 Fig. Forest plot of Mudan granule reducing serum hs-CRP level.
- 618 **S8 Fig. Forest plot of elevated serum SOD level by Mudan granules.**
- 619 **S9** Fig. Forest plot comparing the rate of adverse events in the two groups.



Risk of higs domains

	D1	D2	D3	D4	D5	D6	D7	Overall]		
ľ	-	-	Ξ	-	(+	-	$\overline{}$	Zheng 2016		
	+	Θ	Θ	-	((+)	-	-	Shen 2018		
	+	0	Θ	-	((+)	0	-	Wang 2016		
	+	-	Ξ	-	(+	-	-	Xia 2020		
	+	-	Ξ	-	(+)	•	-	-	Zhang 2021		
	-	—	Ξ	-	+	(+)	0	—	Mi 2013		
Ĩ	+	—	Ξ	-	+	•	0	—	Li 2019		
	-	-	Ξ	-	+	(+)	×	8	Bai 2013		
1	-	-	-	-	+	•	0	-	Dong 2015		
1	+	Θ	Ξ	Ξ	Ŧ	Ŧ	0	Ξ	Zhang 2016		
	-	—	Ξ	-	+	•	8	8	Tian 2011		
	-	-	Ξ	Ξ	+	•	Ξ	-	Lin 2014		
Ĩ	+	—	Ξ	-	+	•	0	—	Tian 2019		
[+	Θ	Ξ	-	+	(+)	0	-	Sun 2022		
ľ	+	—	Ξ	-	+	•	0	—	Zhao 2022		
	Ξ	-	Ξ	Ξ	+	•	Ξ	Ξ	Liu 2015		
1	-	—	Ξ	-	+	•	-	—	Lai 2014		
	•	Ξ	Ξ	Ξ	+	•	Ξ	Ξ	Xie 2012		
	+	—	Ξ	-	+	•	0	Ξ	Chen 2021		
1	medRxiv prep	not certified by peer rev	1101/2023.05 30.232907 iew) is the author/funder	66; this version posted , who has granted med	June 4, 2023, The copyrig Rxiv a license to display the	ht holder for this preprint e preprint in perpetuity.	-	-	Cui 2021		
Ĩ	+	Θ			•	(+)	-	-	Zu 2019		
	•	Θ	Θ	-	•	•	-	-	Deng 2020		
ð	8	Θ	9	Ξ	•	•	Ξ	8	Yu 2022		
Stu	Θ	Θ	Θ	-	•	(Ξ	-	Gao 2018		
	Θ	Θ	Ξ	-	•	•	Ξ	—	Qi 2015		
[•	$\overline{}$	Θ	-	•	•	-	—	QI 2019		
	•	Θ	Ξ	Ξ	•	(Θ	-	Wu 2018		
	•	$\overline{}$	Θ	0	•	(+)	0	Θ	Chang 2017		
[•	9	Θ	0	•	•	0	Θ	Xu 2017		
	0	9	Θ	0	-	(+)	0	Θ	Zou 2013		
[8	9	Θ	-	•	(+)	0		Qu 2016		
[•	$\overline{}$	9	-	•	•	Ξ	$\overline{}$	Xie 2019		
	Θ	Θ	9	-	•	•	Ξ	-	Wu 2015		
	•	9	Θ	-	•	(+)	-	Θ	Yang 2020		
[8	9	Θ	-	•	•	0		Xie 2018		
	8	9	Θ	0	•	(+)	0		Wang 2015		
	•	$\overline{}$	Θ	0	-	•	0	Θ	Chen 2020		
[•	—	Θ	0	•	•	0	Θ	Wu 2021		
	+	9	Θ	0	•	•	0	Θ	Wang 2019		
1									Ener 0045		



Judgement

+ Low Unclear High Critical

- D1: Random sequence generation D2: Allocation concealment
- D3: Blinding of participants and personnel D4: Blinding of outcome assessment D5: Incomplete outcome data D6: Selective reporting D7: Other sources of bias



Study	Treat Yes	ment No	Cor Yes	ntrol No		Ris with	sk Rat 1 95%	io Cl	Weight (%)
Zheng 2016	37	3	30	10		1.23 [1.01	1.511	2 01
Shen 2018	33	1	22	10		1.41	1.11	1.801	1.42
Wang 2016	42	8	37	13		1.14	0.93	1.391	1.93
Xia 2020	77	5	57	24		1.33 [1 15	1.551	3.22
Zhang 2021	46	2	39	9		1.18 [1.02	1.371	3.35
Mi 2013	72	8	62	18		1.16 [1.01	1.331	3.72
Li 2019	30	5	25	10		1 20 [0.94	1 541	1.33
Bai 2013	54	4	40	10		1.16[1.00	1.361	3.10
Dong 2015	24	4	17	9		1.31	0.95	1.801	0.84
Zhang 2016	Rxiv prep	orint doi	https://	/doi.or	n/10.1101/2023.05.30.23290766; this version posted June 4, 2023.	The copyrig	ht holdei e prenrir	r for this p	oreprint
Lin 2014	59	6	43	13	It is made available under a CC-BY 4.0 International license .	1.18	1.00	1.391	2.84
Tian 2019	34	1	22	10		1 41 [1 11	1 801	1.43
Sun 2022	40	2	34	8		1.18[1.00	1.381	2.90
Zhao 2022	33	2	27	8		1.22 [1.00	1.491	2.03
Liu 2015	43	2	34	11		1 26 [1.06	1 511	2.46
Lai 2014	26	4	19	11		1.37 [1.01	1.861	0.91
Xie 2012	73	9	38	28		1.55 [1.24	1.931	1.67
Chen 2021	147	3	136	14	-	1.08 [1.02	1 1 4 1	11 35
Cui 2021	55	5	45	15		1.001	1.02,	1 4 4 1	2.80
Deng 2020	38	3	29	11		1.22 [1.04	1.581	1.84
Yu 2022	40	3	31	12		1 29 [1.05	1.58]	1.94
Gao 2018	95	5	76	24		1 25 [1 11	1 4 1	4 73
Oi 2015	43	7	31	19		139[1.09	1 771	1 39
01 2019	50	6	41	15		1 22 [1.02	1 461	2 35
Wu 2018	52	8	44	16		1 18 [0.99	1 421	2.36
Chang 2017	44	5	36	13		1 22 [1.01	1.42]	2.50
Xu 2017	19	6	14	11		1 36 [0.90	2.051	0.51
Zou 2013	38	2	17	21		-2.12[1.48	3.051	0.66
Xie 2010	30	1	33	7		1 18 [1.02	1 371	3.24
Vang 2020	78	22	39	21		1 20 [0.97	1 481	1 79
Wang 2015	40	5	28	17		1 43 [1 11	1.831	1 33
Chen 2020	30	5	22	13		1361	1.02	1.821	1.02
Wu 2021	22	3	16	9		1 38 [0.99	1 911	0.80
Wu 2021	33	1	27	7		1.30 [1.02	1 461	2 39
Wang 2019	38	3	33	8		1 15 [0.97	1.371	2.56
Feng 2015	71	5	60	16		1 18 [1.04	1 351	4 11
Oi 2015	27	5	20	12		1351	0.99	1.841	0.90
Lu 2021	76	4	57	23		1.33 [1 15	1.551	3.36
Zhu 2017	43	3	35	11		1 23 [1.03	1 471	2 43
Wang 2019	92	7	78	21		1 18 [1.05	1.321	4.93
Xiao 2016	46	4	36	14		1.28[1.05,	1.551	2 16
0	10		00			1.201	1.00,	1.00]	2.10
Overall	2		2		▼ 1 ² 1 05	1.23 [1.19,	1.27]	
Technologic	T = (0.00,1	= 2	0.009	%, T = 1.25				
Test of $\Theta_i = \Theta_i$. Q(40)	05	.46, p	= 0.	20				
Test of $\theta = 0$:	2 = 12	.95, p	= 0.0	0		-			
Random-effect	s REM	IL mo	del		1 2 Favours RT Favours Mudan + RT				



Weights: Inverse-variance

Funnel plot



and TGF- β_1 levels

Reducing the inflammatory response

Improving sciatic nerve conduction velocity

Mudan Granules

Diabetes Model

Improving peripheral nerve injury by TLR4/MyD88/NFκB and TLR4/p38 MAPK pathways

Increasing GSH and SOD levels and reducing MDA levels

Alleviating neuropathic pain by PI3K/AKT pathway